SpringWorks Therapeutics Inc (SWTX) concluded trading on Thursday at a closing price of $46.76, with 4.76 million shares of worth about $222.39 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 11.68% during that period and on June 12, 2025 the price saw a gain of about 0.02%. Currently the company’s common shares owned by public are about 74.99M shares, out of which, 72.94M shares are available for trading.
Stock saw a price change of -0.09% in past 5 days and over the past one month there was a price change of 1.17%. Year-to-date (YTD), SWTX shares are showing a performance of 29.42% which increased to 16.99% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $28.21 but also hit the highest price of $62.00 during that period. The average intraday trading volume for SpringWorks Therapeutics Inc shares is 5.00 million. The stock is currently trading 0.45% above its 20-day simple moving average (SMA20), while that difference is up 6.26% for SMA50 and it goes to 14.49% higher than SMA200.
SpringWorks Therapeutics Inc (NASDAQ: SWTX) currently have 74.99M outstanding shares and institutions hold larger chunk of about 98.04% of that.
The stock has a current market capitalization of $3.52B and its 3Y-monthly beta is at 0.69. It has posted earnings per share of -$3.41 in the same period. It has Quick Ratio of 4.18 while making debt-to-equity ratio of 0.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SWTX, volatility over the week remained 0.06% while standing at 0.20% over the month.
Analysts are in expectations that SpringWorks Therapeutics Inc (SWTX) stock would likely to be making an EPS of -0.97 in the current quarter, while forecast for next quarter EPS is -1.05 and it is -1.15 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.97 which is -0.97 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.54 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 20.99% while it is estimated to increase by 69.98% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Evercore ISI on November 20, 2024 offering an Outperform rating for the stock and assigned a target price of $60 to it. Coverage by Guggenheim stated SpringWorks Therapeutics Inc (SWTX) stock as a Buy in their note to investors on February 05, 2024, suggesting a price target of $75 for the stock. On December 01, 2022, BofA Securities Initiated their recommendations, while on January 19, 2021, H.C. Wainwright Reiterated their ratings for the stock with a price target of $101. Stock get a Buy rating from H.C. Wainwright on October 29, 2020.
